secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eikon Therapeutics, Inc. (EIKN)
CIK:        0001861123
Form:       8-K
Filed at:   2026-06-01T11:30:25+00:00
Accession:  0001193125-26-249725
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel
--------------------------------------------------------------------------------

- TeLuRide-005 Phase 2: ORR 63.1%, DCR 90.8% in 1L stage 4 NSCLC (n=65 evaluable).
- Non-squamous cohort: ORR 55.6%, DCR 83.3%, median DOR >11 months at 13.6 months follow-up.
- Squamous cohort: ORR 72.4%, DCR 100% with median follow-up 8.8 months (data maturing).
- EIK1003 monotherapy (Cohort 1A): ORR 14.3% overall (26.7% PARP-naïve), median DOR 7.8 months in responders.
- EIK1003 + paclitaxel (Cohort 1C): ORR 24.5% (29.6% in platinum-resistant ovarian, 19.2% in breast).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/0001193125-26-249725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/eikn-20260530.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-249725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer